Kelly Berg

Dr. Kelly Berg


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2001 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
KBKelly Berg
Kelly Berg
JCJodie D Cropper
Jodie D Cropper
CNColleen M Niswender
Colleen M Niswender
ESElaine Sanders‐Bush
Elaine Sanders‐Bush
RERonald B Emeson
Ronald B Emeson
WCWilliam P Clarke
William P Clarke
The serotonin2C (5‐HT2C) receptor couples to both phospholipase C (PLC)‐inositol phosphate (IP) and phospholipase A2 (PLA2)‐arachidonic acid (AA) signalling cascades. Agonists can differentially activate these effectors (i.e. agonist‐directed trafficking of receptor stimulus) perhaps due to agonist‐specific receptor conformations which differentially couple to/activate transducer molecules (e.g. G proteins). Since editing of RNA transcripts of the human 5‐HT2C receptor leads to substitution of amino acids at positions 156, 158 and 160 of the putative second intracellular loop, a region important for G protein coupling, we examined the capacity of agonists to activate both the PLC‐IP and PLA2‐AA pathways in CHO cells stably expressing two major, fully RNA‐edited isoforms (5‐HT2C‐VSV, 5‐HT2C‐VGV) of the h5‐HT2C receptor. 5‐HT increased AA release and IP accumulation in both 5‐HT2C‐VSV and 5‐HT2C‐VGV expressing cells. As expected, the potency of 5‐HT for both RNA‐edited isoforms for both responses was 10 fold lower relative to that of the non‐edited receptor (5‐HT2C‐INI) when receptors were expressed at similar levels. Consistent with our previous report, the efficacy order of two 5‐HT receptor agonists (TFMPP and bufotenin) was reversed for AA release and IP accumulation at the non‐edited receptor thus demonstrating agonist trafficking of receptor stimulus. However, with the RNA‐edited receptor isoforms there was no difference in the relative efficacies of TFMPP or bufotenin for AA release and IP accumulation suggesting that the capacity for 5‐HT2C agonists to traffic receptor stimulus is lost as a result of RNA editing. These results suggest an important role for the second intracellular loop in transmitting agonist‐specific information to signalling molecules. British Journal of Pharmacology (2001) 134, 386–392; doi:10.1038/sj.bjp.0704255

1 February 2012 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
KBKelly Berg
Kelly Berg
MRMatthew P. Rowan
Matthew P. Rowan
AGAchla Gupta
Achla Gupta
TSTeresa A. Sanchez
Teresa A. Sanchez
MSMichelle Silva
Michelle Silva
WCWilliam P. Clarke
William P. Clarke
The peripheral δ opioid receptor (DOR) is an attractive target for analgesic drug development. There is evidence that DOR can form heteromers with the κ-opioid receptor (KOR). As drug targets, heteromeric receptors offer an additional level of selectivity and, because of allosteric interactions between protomers, functionality. Here we report that selective KOR antagonists differentially altered the potency and/or efficacy of DOR agonists in primary cultures of adult rat peripheral sensory neurons and in a rat behavioral model of thermal allodynia. In vitro, the KOR antagonist nor-binaltorphimine (nor-BNI) enhanced the potency of [d-Pen2,5]-enkephalin (DPDPE), decreased the potency of [d-Ala2,d-Leu5]-enkephalin (DADLE), and decreased the potency and efficacy of 4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide (SNC80) to inhibit prostaglandin E2 (PGE2)-stimulated adenylyl cyclase activity. In vivo, nor-BNI enhanced the effect of DPDPE and decreased the effect of SNC80 to inhibit PGE2-stimulated thermal allodynia. In contrast to nor-BNI, the KOR antagonist 5′-guanidinonaltrindole (5′-GNTI) reduced the response of DPDPE both in cultured neurons and in vivo. Evidence for DOR-KOR heteromers in peripheral sensory neurons included coimmunoprecipitation of DOR with KOR, a DOR-KOR heteromer selective antibody augmented the antinociceptive effect of DPDPE in vivo, and the DOR-KOR heteromer agonist 6′-GNTI inhibited adenylyl cyclase activity in vitro as well as PGE2-stimulated thermal allodynia in vivo. Taken together, these data suggest that DOR-KOR heteromers exist in rat primary sensory neurons and that KOR antagonists can act as modulators of DOR agonist responses most likely through allosteric interactions between the protomers of the DOR-KOR heteromer.

27 August 2015 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
LSLaura C. Sullivan
Laura C. Sullivan
WCWilliam P Clarke
William P Clarke
KBKelly Berg
Kelly Berg
It is now well accepted that receptors can regulate cellular signaling pathways in the absence of a stimulating ligand, and inverse agonists can reduce this ligand-independent or “constitutive” receptor activity. Both the serotonin 5-HT2A and 5-HT2C receptors have demonstrated constitutive receptor activity in vitro and in vivo. Each has been identified as a target for treatment of schizophrenia. Further, most, if not all, atypical antipsychotic drugs have inverse agonist properties at both 5-HT2A and 5-HT2C receptors. This paper describes our current knowledge of inverse agonism of atypical antipsychotics at 5-HT2A/2C receptor subtypes in vitro and in vivo. Exploiting inverse agonist properties of APDs may provide new avenues for drug development.

1 November 2001 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
KBKelly Berg
Kelly Berg
BSBrian D. Stout
Brian D. Stout
SMSaul Maayani
Saul Maayani
WCWilliam P. Clarke
William P. Clarke

1 March 2008 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
KBKelly Berg
Kelly Berg
JDJohn Dunlop
John Dunlop
TSTeresa Sanchez
Teresa Sanchez
MSMichelle Silva
Michelle Silva
WCWilliam P. Clarke
William P. Clarke
The post-transcriptional process of mRNA editing changes up to three amino acids in the second intracellular domain (i2) of the serotonin2C (5-HT2C) receptor and alters some signaling characteristics of the receptor. Here, we report that the substitution of valine for isoleucine (I156V; 5-HT2C-VNI), which occurs naturally as a result of mRNA editing, alters both ligand-dependent and -independent signaling. Agonist functional selectivity at the 5-HT2C-VNI receptor differed from the nonedited 5-HT2C-INI receptor. Ligands with selectivity for phospholipase C (PLC) signaling in 5-HT2C-INI cells retained this selectivity in 5-HT2C-VNI-expressing cells. However, ligands with selectivity for phospholipase A2 (PLA2) signaling in 5-HT2C-INI cells lost the capacity for preferential PLA2 activation in 5-HT2C-VNI cells. Maximal PLC responses elicited by 5-HT (full agonist) and lysergic acid diethylamide and 2,5-dimethoxy-4-iodophenylisopropylamine (partial agonists) at edited receptors (5-HT2C-VNI, 5-HT2C-VSV, and 5-HT2C-VGV) were not different from 5-HT2C-INI receptors, suggesting that the capacity of the agonist-occupied receptor to couple to Gq/11 proteins was not different. Ligand-independent (i.e., constitutive) receptor activity toward PLC for the 5-HT2C-VNI receptor was markedly reduced to a level similar to that for the fully edited 5-HT2C-VSV isoform. However, there was no difference in the thermal stability of the edited receptors, suggesting that mRNA editing does not alter the capacity of receptors to adopt active conformations. These results indicate that a conservative change in one amino acid (I156V) located in i2 of the 5-HT2C receptor produces profound changes in receptor function that differ depending upon whether the receptor is unoccupied or occupied by agonist.

1 October 2006 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
KBKelly Berg
Kelly Berg
SNSylvia Navailles
Sylvia Navailles
TSTeresa A. Sanchez
Teresa A. Sanchez
YSYamille M. Silva
Yamille M. Silva
MWMartyn D. Wood
Martyn D. Wood
WCWilliam P. Clarke
William P. Clarke
5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) is a selective, high-affinity 5-hydroxytryptamine (serotonin)2C receptor ligand that has been previously characterized as a competitive 5-HT2C receptor antagonist that has a long duration of activity in vivo. It is active in two preclinical models of anxiety and has an improved anxiolytic profile compared with benzodiazepines. In this study, we further characterized the pharmacological properties of SB 243213 by measuring its effects on each of multiple responses coupled to the 5-HT2C receptor. In Chinese hamster ovary cells, SB 243213 was an inverse agonist for the phospholipase A2 response, for guanosine 5′-O-(3-[35S]thio)triphosphate binding, for reduction of constitutive desensitization, and for enhancement of dopamine release in the rat nucleus accumbens, with relative efficacies of 0.6, 1, 1, and 0.6, respectively. However, for the phospholipase C (PLC) signaling cascade, SB 243213 behaved as an antagonist. Although SB 243213 was previously characterized as a competitive antagonist for the PLC response, the magnitude of the dextral shift of the 5-HT concentration-response curve was time-dependent, and the maximal PLC response to 5-HT was decreased, probably as a result of the slow dissociation rate of SB 243213 (initial dissociation rate was 3.2 times slower than SB206553, a prototypical 5-HT2C receptor inverse agonist). Taken together, these data show that the pharmacological characteristics of SB 243213 at the 5-HT2C receptor differ depending upon the response measured, and they support the hypothesis that different drugs, acting at the same receptor subtype, can differentially regulate multiple cellular signaling systems.